Biology Reference
In-Depth Information
90. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-
Fridman C, Fridman WH.
negative breast
cancer. Cancer Res
2008;68(13):
ltration in
human tumors: a prognostic factor that should not be
ignored. Oncogene 2010;29(8):1093
Immune in
13.
101. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intra-
tumoral T cells, recurrence, and survival in epithelial
ovarian cancer. N Engl J Med 2003;348(3):203
5405
e
102.
91. Menetrier-Caux C, Montmain G, Dieu MC, et al.
Inhibition of the differentiation of dendritic cells from
CD34(
e
13.
102. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-
term survival for patients with non-small-cell lung
cancer with intratumoral lymphoid structures. J Clin
Oncol 2008;26(27):4410
e
) progenitors by tumor
cells:
role
of
þ
interleukin-6 and macrophage
colony-stimulating
91.
92. Dranoff G. Cytokines in cancer pathogenesis and
cancer therapy. Nat Rev Cancer 2004;4(1):11
factor. Blood 1998;92(12):4778
7.
103. Milne K, Kobel M, Kalloger SE, et al. Systematic
analysis of immune in
e
e
22.
93. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-
stimulating factor 1 promotes progression of mammary
tumors to malignancy. J Exp Med 2001;193(6):727
ltrates in high-grade serous
ovarian cancer reveals CD20, FoxP3 and TIA-1 as
positive prognostic factors. PLoS ONE 2009;4(7):e6412.
104. Nelson BH. CD20
e
40.
94. Pollard JW. Tumour-educated macrophages promote
tumour progression and metastasis. Nat Rev Cancer
2004;4(1):71
B cells: the other tumor-in
ltrating
e
þ
82.
105. Willis SN, Mallozzi SS, Rodig SJ, et al. The microen-
vironment of germ cell tumors harbors a prominent
antigen-driven humoral response.
lymphocytes. J Immunol 2010;185(9):4977
e
8.
95. Zou W. Immunosuppressive networks in the tumour
environment and their therapeutic relevance. Nat Rev
Cancer 2005;5(4):263
e
J
Immunol 2009;
7.
106. Bianchini G, Qi Y, Alvarez RH, et al. Molecular
anatomy of breast cancer stroma and its prognostic
value in estrogen receptor-positive and -negative
cancers. J Clin Oncol 2010;28(28):4316
182(5):3310
e
74.
96. Zou W. Regulatory T cells, tumour immunity and
immunotherapy. Nat Rev Immunol 2006;6(4):295
e
307.
97. Dave SS, Wright G, Tan B, et al. Prediction of survival
in follicular lymphoma based on molecular features of
tumor-in
e
23.
107. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S,
Morton DL. Tumor-associated antigen TA90 immune
complex assay predicts recurrence and survival after
surgical treatment of stage I
e
ltrating immune cells. N Engl J Med 2004;
351(21):2159
69.
98. Galon J, Costes A, Sanchez-Cabo F, et al. Type,
density, and location of immune cells within human
colorectal tumors predict clinical outcome. Science
2006;313(5795):1960
e
III melanoma. J Clin
e
82.
108. Anderson KS, Wong J, Vitonis A, et al. p53 autoanti-
bodies as potential detection and prognostic
biomarkers in serous ovarian cancer. Cancer Epidemiol
Biomarkers Prev 2010;19(3):859
Oncol 2001;19(4):1176
e
4.
99. Pages F, Berger A, Camus M, et al. Effector memory T
cells, early metastasis, and survival
e
in colorectal
68.
109. Anderson KS, LaBaer J. The sentinel within: exploiting
the immune system for cancer biomarkers. J Proteome
Res 2005;4(4):1123
e
66.
100. Schmidt M, Bohm D, von Torne C, et al. The humoral
immune system has a key prognostic impact in node-
cancer. N Engl J Med 2005;353(25):2654
e
33.
e
Search WWH ::
Custom Search